Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. [electronic resource]
Producer: 20140306Description: 233-44 p. digitalISSN:- 1365-2141
- Adaptor Proteins, Signal Transducing
- Alternative Splicing
- Antibodies, Monoclonal -- immunology
- Antibody Specificity -- immunology
- Biomarkers, Tumor -- genetics
- Cell Line, Tumor
- Drug Resistance, Neoplasm -- genetics
- Humans
- Multiple Myeloma -- drug therapy
- Peptide Hydrolases -- genetics
- RNA Isoforms
- Thalidomide -- analogs & derivatives
- Ubiquitin-Protein Ligases
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.